Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification

Cancer Imaging

Table 2 Univariate and Multivariate Analyses of Risk Factors for Second Recurrence in the 361 Patients

Variables	Univariate	Multivariate	Variable	Univariate	Multivariate
Variables	P-value	P-value	Variable	P-value	P-value
Factors at primary HCC			Factors at initial recurrence
Male	0.092		Male	0.092
Age, years	0.121		Age, years	0.222
pBCLC stage (0/A/B)	0.408		rBCLC stage (0/A/B)	< 0.001*	< 0.001*
HGB, g/L	0.184		HGB, g/L	0.309
NLR	0.331		NLR	0.632
PLT, 10⁹/L	0.449		PLT, 10⁹/L	0.295
WBC, 10⁹/L	0.122		WBC, 10⁹/L	0.140
AFP, ng/ml (≤200/> 200)	0.207		AFP, ng/ml (≤200/> 200)	0.133
CA 19–9, U/mL	0.505		CA 19–9, U/mL	0.218
CEA, ng/mL	0.200		CEA, ng/mL	0.168
AST, U/L	0.713		AST, U/L	0.022*	0.161
CRE, umol	0.543		CRE, umol	0.339
ALBI grade (I/II)	0.054		ALBI grade (I/II)	0.111
Child-Pugh stage (I/II)	0.892		Child-Pugh stage (I/II)	0.385
Treatment (resection/ablation)	0.075		First RFS, years (≤1/> 1)	0.003*	0.002*
			Pre-TACE (with/without)	0.161

pBCLC stage BCLC stage for primary HCC, NLR neutrophil to lymphocyte ratio, ALBI grade albumin-bilirubin grade, rBCLC stage BCLC stage for initial recurrent HCC, first RFS first recurrence-free survival, pre-TACE transcatheter arterial chemoembolization before ablation for initial recurrent HCC

ISSN: 1470-7330